InflaRx (IFRX) News Today $0.73 -1.09 (-59.86%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$0.76 +0.03 (+3.76%) As of 07:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why is InflaRx Dropping Today?InflaRx (IFRX) shares have moved lower after the company announced the discontinuation of its Phase 3 trial of vilobelimab in pyoderma gangrenosum due to futility. The clinical setback and widespread media coverage drove a sharp sell-off, though short interest has declined and the company is refocusing on its next asset to extend its cash runway. Key factors: Short interest fell by 12.2% in May, potentially reflecting reduced bearish positioning Company is shifting development efforts to INF904 as part of a strategy to extend its cash runway One report of zero short interest and an undefined change suggests data anomalies in some market statistics Independent Data Monitoring Committee recommended stopping the vilobelimab Phase 3 trial for futility after interim analysis Shares plunged following the announcement to halt and discontinue the lead asset program Multiple outlets have labeled the Phase 3 failure a significant setback for the company’s complement-targeting pipeline Posted 7h agoAI Generated. May Contain Errors. IFRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period InflaRx N.V.: InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma GangrenosumMay 28 at 11:58 PM | finanznachrichten.deInflaRx plunges on plans to halt studies into lead asset in rare skin disorderMay 28 at 11:58 PM | msn.comInflaRx Stock (IFRX) Plummets 55% on Clinical FailureMay 28 at 4:31 PM | tipranks.comInflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin DiseaseMay 28 at 11:19 AM | benzinga.comInflaRx (NASDAQ:IFRX) Shares Acquired by Northern Trust CorpNorthern Trust Corp boosted its position in InflaRx (NASDAQ:IFRX - Free Report) by 1,933.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 666,845 shares of the company's stock after purchasing an addiMay 28 at 3:08 AM | marketbeat.comInflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma ...May 28 at 2:16 AM | gurufocus.comInflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma GangrenosumMay 28 at 1:30 AM | globenewswire.comInflaRx to Participate in Upcoming Investor ConferencesMay 22, 2025 | globenewswire.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Position in InflaRx (NASDAQ:IFRX)OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its stake in InflaRx (NASDAQ:IFRX - Free Report) by 21.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 625,589 shares of theMay 16, 2025 | marketbeat.comFY2025 EPS Estimates for InflaRx Raised by Cantor FitzgeraldInflaRx (NASDAQ:IFRX - Free Report) - Research analysts at Cantor Fitzgerald raised their FY2025 EPS estimates for InflaRx in a note issued to investors on Thursday, May 8th. Cantor Fitzgerald analyst S. Seedhouse now forecasts that the company will post earnings of ($0.70) per share for the yearMay 13, 2025 | marketbeat.comQ2 Earnings Forecast for InflaRx Issued By Leerink PartnrsInflaRx (NASDAQ:IFRX - Free Report) - Stock analysts at Leerink Partnrs decreased their Q2 2025 earnings per share (EPS) estimates for InflaRx in a research note issued on Wednesday, May 7th. Leerink Partnrs analyst J. Schwartz now expects that the company will earn ($0.24) per share for the quarMay 13, 2025 | marketbeat.comInflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024)May 11, 2025 | sg.finance.yahoo.comOppenheimer Initiates Coverage of InflaRx N.V. (IFRX) with Outperform RecommendationMay 9, 2025 | msn.comOppenheimer Initiates Coverage on InflaRx (IFRX) with "Outperform" Rating | IFRX ...May 8, 2025 | gurufocus.comInflaRx Reports Q1 2025 Financial Results with Reduced LossesMay 7, 2025 | tipranks.comInflaRx N.V.: InflaRx Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | finanznachrichten.deInflaRx Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 7, 2025 | globenewswire.com2IFRX : Preview: InflaRx's EarningsMay 6, 2025 | benzinga.comRaymond James Financial Inc. Makes New Investment in InflaRx (NASDAQ:IFRX)Raymond James Financial Inc. bought a new position in InflaRx (NASDAQ:IFRX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 638,092 shares of the company's stock, valued atMay 5, 2025 | marketbeat.comInflaRx (IFRX) Projected to Post Quarterly Earnings on WednesdayInflaRx (NASDAQ:IFRX) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-7-inflarx-stock/)May 4, 2025 | marketbeat.comCantor Fitzgerald Forecasts InflaRx FY2025 EarningsInflaRx (NASDAQ:IFRX - Free Report) - Cantor Fitzgerald issued their FY2025 earnings estimates for shares of InflaRx in a report released on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will post earnings of ($0.87) per share for the year. Cantor FitzgeraldMay 3, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage on InflaRx (NASDAQ:IFRX)Cantor Fitzgerald started coverage on InflaRx in a report on Tuesday. They set an "overweight" rating and a $10.00 price objective for the company.May 1, 2025 | marketbeat.comInflaRx to Report First Quarter 2025 Results on May 7, 2025 | IFRX Stock NewsApril 30, 2025 | gurufocus.comInflaRx to Report First Quarter 2025 Results on May 7, 2025April 30, 2025 | gurufocus.comInflaRx to Report First Quarter 2025 Results on May 7, 2025April 30, 2025 | globenewswire.comCantor Fitzgerald Initiates Coverage of InflaRx N.V. (IFRX) with Overweight RecommendationApril 30, 2025 | msn.comBiotech Shares Jump As Institutional Coverage Begins With Positive OutlookApril 29, 2025 | msn.comInflaRx Approves Key Resolutions at Annual Shareholder MeetingApril 24, 2025 | tipranks.comEversept Partners LP Has $1.22 Million Stock Position in InflaRx (NASDAQ:IFRX)Eversept Partners LP lessened its holdings in InflaRx (NASDAQ:IFRX - Free Report) by 69.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 492,452 shares of the company's stock afApril 24, 2025 | marketbeat.comInflaRx (NASDAQ:IFRX) Short Interest Up 36.8% in MarchInflaRx (NASDAQ:IFRX - Get Free Report) saw a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 794,600 shares, a growth of 36.8% from the March 15th total of 581,000 shares. Based on an average daily volume of 391,800 shares, the short-interest ratio is presently 2.0 days. Approximately 1.4% of the shares of the stock are sold short.April 21, 2025 | marketbeat.comInflaRx N.V. Announces 2025 Annual General Meeting AgendaApril 3, 2025 | tipranks.comRaymond James Financial Inc. Purchases Shares of 638,092 InflaRx (NASDAQ:IFRX)Raymond James Financial Inc. acquired a new position in InflaRx (NASDAQ:IFRX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 638,092 shares of the company's stock, valued at approximately $1,576,000.April 3, 2025 | marketbeat.comIs InflaRx (IFRX) the Best German Stock to Buy According to Hedge Funds?April 2, 2025 | msn.comInflaRx price target raised to $10 from $7 at GuggenheimMarch 27, 2025 | markets.businessinsider.comGuggenheim Raises InflaRx (NASDAQ:IFRX) Price Target to $10.00Guggenheim lifted their target price on InflaRx from $7.00 to $10.00 and gave the stock a "buy" rating in a report on Wednesday.March 27, 2025 | marketbeat.comLifeSci Capital Remains a Hold on InflaRx (IFRX)March 22, 2025 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for InflaRx (NASDAQ:IFRX)HC Wainwright reiterated a "buy" rating and issued a $8.00 price target on shares of InflaRx in a research report on Friday.March 22, 2025 | marketbeat.comInflaRx N.V. Receives European Commission Approval for GOHIBIC® (vilobelimab) and Achieves Key Development Milestones in Clinical TrialsMarch 22, 2025 | nasdaq.comInflaRx reports Q EPS (EUR 0.78) vs (EUR 0.78) last yearMarch 21, 2025 | markets.businessinsider.comInflaRx (NASDAQ:IFRX) Posts Quarterly Earnings ResultsInflaRx (NASDAQ:IFRX - Get Free Report) issued its earnings results on Thursday. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%.March 21, 2025 | marketbeat.comPromising Prospects for InflaRx’s Gohibic: Buy Rating Supported by Positive Phase 3 Developments and Market PotentialMarch 21, 2025 | tipranks.comInflaRx N.V. Reports 2024 Results and Key AchievementsMarch 21, 2025 | tipranks.comInflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected MilestonesMarch 20, 2025 | markets.businessinsider.comInflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected MilestonesMarch 20, 2025 | globenewswire.comShort Interest in InflaRx (NASDAQ:IFRX) Grows By 46.2%InflaRx (NASDAQ:IFRX - Get Free Report) was the target of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 564,700 shares, a growth of 46.2% from the February 13th total of 386,300 shares. Based on an average trading volume of 382,600 shares, the short-interest ratio is currently 1.5 days. Approximately 1.0% of the shares of the company are sold short.March 16, 2025 | marketbeat.comInflaRx (IFRX) Projected to Post Earnings on ThursdayInflaRx (NASDAQ:IFRX) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for InflaRx (NASDAQ:IFRX)HC Wainwright reiterated a "buy" rating and set a $8.00 price objective on shares of InflaRx in a research note on Friday.March 8, 2025 | marketbeat.comInflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual MeetingMarch 7, 2025 | finance.yahoo.comInflaRx announces presentation of multiple posters on utility of vilobelimabMarch 7, 2025 | markets.businessinsider.comInflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual MeetingMarch 7, 2025 | gurufocus.com Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address IFRX Media Mentions By Week IFRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IFRX News Sentiment▼0.480.87▲Average Medical News Sentiment IFRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IFRX Articles This Week▼102▲IFRX Articles Average Week Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Tyra Biosciences News Today Upstream Bio News Today Kura Oncology News Today REGENXBIO News Today Arvinas News Today Amylyx Pharmaceuticals News Today Zevra Therapeutics News Today Altimmune News Today Cullinan Therapeutics News Today ORIC Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IFRX) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
